Atogepant is a selective, orally active calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of migraine in adults. It is a small-molecule pharmaceutical active ingredient.
Atogepant has the molecular formula C₂₉H₂₃F₆N₅O₃ and a molecular weight of approximately 603.5 g/mol. It is described as a white to off-white powder.
Atogepant is used as an active pharmaceutical ingredient in formulations intended for:
The approved product QULIPTA® contains atogepant in 10 mg, 30 mg and 60 mg tablet strengths in the United States.
Atogepant is freely soluble in ethanol, soluble in methanol, sparingly soluble in acetone, slightly soluble in acetonitrile and practically insoluble in water.
Atogepant API should be manufactured, tested and released according to the applicable pharmacopoeial, regulatory and customer-approved specifications, including validated identification, assay, related substances, residual solvents and elemental impurity controls where applicable.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white powder |
| Identification | Conforms to identification tests for Atogepant |